TY - JOUR
T1 - TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia
T2 - six-year follow-up of the GCLLSG CLL3X trial.
AU - Dreger, Peter
AU - Schnaiter, Andrea
AU - Zenz, Thorsten
AU - Böttcher, Sebastian
AU - Rossi, Marianna
AU - Paschka, Peter
AU - Bühler, Andreas
AU - Dietrich, Sascha
AU - Busch, Raymonde
AU - Ritgen, Matthias
AU - Bunjes, Donald
AU - Zeis, Matthias
AU - Stadler, Michael
AU - Uharek, Lutz
AU - Scheid, Christof
AU - Hegenbart, Ute
AU - Hallek, Michael
AU - Kneba, Michael
AU - Schmitz, Norbert
AU - Döhner, Hartmut
AU - Stilgenbauer, Stephan
PY - 2013/4/18
Y1 - 2013/4/18
N2 - The purpose of this analysis was to provide 6-year follow-up of the CLL3X trial, which studied reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk chronic lymphocytic leukemia (CLL), and to investigate the effect of TP53, SF3B1, and NOTCH1 mutations on HSCT outcome. For 90 allografted patients, 6-year overall survival (OS) was 58% and 6-year event-free survival (EFS) was 38%. TP53, SF3B1, and NOTCH1 mutations were found in 30%, 26%, and 14% of the trial population, respectively. By univariate and multivariate analyses, the mutational status of the TP53, SF3B1, and NOTCH1 genes had no significant effect on OS and EFS. Studies of minimal residual disease confirmed durability of CLL eradication in mutated patients. We conclude that HSCT can provide long-term disease control in patients with poor-risk CLL independent of the presence of TP53, SF3B1, and NOTCH1 mutations. The trial has been registered at the US National Cancer Institute as #EU-20554, NCT00281983.
AB - The purpose of this analysis was to provide 6-year follow-up of the CLL3X trial, which studied reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk chronic lymphocytic leukemia (CLL), and to investigate the effect of TP53, SF3B1, and NOTCH1 mutations on HSCT outcome. For 90 allografted patients, 6-year overall survival (OS) was 58% and 6-year event-free survival (EFS) was 38%. TP53, SF3B1, and NOTCH1 mutations were found in 30%, 26%, and 14% of the trial population, respectively. By univariate and multivariate analyses, the mutational status of the TP53, SF3B1, and NOTCH1 genes had no significant effect on OS and EFS. Studies of minimal residual disease confirmed durability of CLL eradication in mutated patients. We conclude that HSCT can provide long-term disease control in patients with poor-risk CLL independent of the presence of TP53, SF3B1, and NOTCH1 mutations. The trial has been registered at the US National Cancer Institute as #EU-20554, NCT00281983.
UR - http://www.scopus.com/inward/record.url?scp=84879173666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879173666&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-11-469627
DO - 10.1182/blood-2012-11-469627
M3 - Article
C2 - 23435461
AN - SCOPUS:84879173666
VL - 121
SP - 3284
EP - 3288
JO - Blood
JF - Blood
SN - 0006-4971
IS - 16
ER -